Throughout the pandemic, BIO has been working to better understand where key manufacturing capabilities and capacity lie, and help companies find needed partners. As part of this effort, we launched a new tool to help biopharma companies and contract development and manufacturing organizations (CDMOs) find potential manufacturing partners for COVID-19 products.
BIO’s COVID-19 Therapeutics Manufacturing Capability Search Toolis an online tool to allow companies who are developing COVID-19 therapeutics and need external support to quickly identify a shortlist of potential partners with the required capabilities.
What can you do? Select and search for multiple capabilities at one time, including manufacturing and development capabilities for monoclonal antibodies, sterile injectables, and oral solids.
What do you get? Your search will generate a list of relevant companies matching your criteria, along with contact information. And we will continue to add additional companies as we receive more information.
To access it, visit the BIO Coronavirus Hub and create a free account.
If you want your company to be part of the search tool, email coronavirus@bio.org.
As a reminder, BIO has a suite of COVID-19 resources, including the pipeline tracker, business and scientific resources, and a list of patient support programs. If you have anything you think should be added to the site, email coronavirus@bio.org.
More Health Care News:
Axios: America's failed coronavirus response hurts people of color most
“These disparities stem from deep-rooted racial inequities that are baked into every part of American life, and fixing these will take a long time. But bringing the pandemic under control isn't as hard—almost every other wealthy country in the world has been able to do it by this point. America's decision not to follow suit will continue to deepen its racial wounds until it changes course.”
STAT News: Sanofi CEO Paul Hudson on a major acquisition, long-term strategy, and COVID-19 vaccines
Sanofi's new CEO spoke “about the decision to purchase Principia Biopharma for $3.7 billion—as well as Sanofi’s overall strategy and its COVID-19 vaccine candidates.”
The New York Times: Federal study of COVID treatments enters new phase
“A clinical trial showed that remdesivir helped hospitalized patients. Now researchers are asking whether when the drug is paired with another antiviral drug, patients will recover faster.”